Thrombotic microangiopathy in the course of catastrophic antiphospholipid syndrome successfully treated with eculizumab: case report and systematic review of the literature

Lupus. 2020 May;29(6):631-639. doi: 10.1177/0961203320917460. Epub 2020 Apr 6.

Authors

Marta Skoczynska¹, Mark A Crowther², Malgorzata Chowaniec^{3

4}, Monika Ponikowska³, Shruti Chaturvedi⁵, Kimberly Legault²

Affiliations

¹ Department and Clinic of Rheumatology and Internal Medicine, Wroclaw Medical University, Wroclaw, Poland.
² Department of Medicine, McMaster University, Hamilton, Canada.
³ Department of Rheumatology and Internal Medicine, Wroclaw University Hospital, Wroclaw, Poland.
⁴ Department of Hygiene, Wroclaw Medical University, Wroclaw, Poland.
⁵ Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, USA.

PMID: 32252584
DOI: 10.1177/0961203320917460

No abstract available

Keywords: Catastrophic antiphospholipid syndrome; eculizumab.

Publication types

Case Reports
Systematic Review

MeSH terms

Adult
Aged
Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / therapeutic use*
Antiphospholipid Syndrome / complications
Complement C5 / drug effects
Female
Humans
Lupus Erythematosus, Systemic / complications
Lupus Erythematosus, Systemic / diagnosis*
Male
Middle Aged
Remission Induction
Severity of Illness Index
Thrombotic Microangiopathies / drug therapy*
Thrombotic Microangiopathies / etiology
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Complement C5
eculizumab